Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 10,600 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 287,363 shares of the biopharmaceutical company’s stock after selling 10,600 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Gilead Sciences were worth $26,544,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. State Street Corp grew its position in Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after acquiring an additional 841,776 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after buying an additional 11,665,593 shares during the last quarter. FMR LLC lifted its stake in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after buying an additional 14,680,161 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Gilead Sciences by 2.1% in the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock worth $2,302,119,000 after buying an additional 574,421 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Gilead Sciences by 3.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company’s stock worth $650,009,000 after buying an additional 224,960 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 713,000 shares of company stock valued at $67,945,181 over the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 0.1 %

GILD stock opened at $109.95 on Friday. The stock has a fifty day moving average of $95.41 and a 200-day moving average of $88.73. The company has a market capitalization of $137.03 billion, a price-to-earnings ratio of 297.16, a PEG ratio of 0.71 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $111.03.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.87%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 832.43%.

Wall Street Analysts Forecast Growth

GILD has been the subject of several research analyst reports. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Morgan Stanley upped their target price on shares of Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Citigroup initiated coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 target price for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $102.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.